RedHill Biopharma (NASDAQ:RDHL)

1:30 PM - 1:45 PM, Monday, June 3, 2019 ・ Theater 2
RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company, primarily focused on gastrointestinal diseases. RedHill commercializes and promotes four gastrointestinal products in the U.S. RedHill has a robust and de-risked clinical late-stage pipeline with several Phase 3 and Phase 2-stage drugs in development. RedHill has successfully completed four Phase 3 studies (2x Talicia® (RHB-105) for H. pylori infection, RHB-104 for Crohn’s disease & BEKINDA® (RHB-102) for gastroenteritis). RedHill plans to file an NDA for Talicia® for H. pylori infection in H1/2019 (eligible for 6-month priority review) and expects to launch Talicia® in Q4/2019, subject to FDA approval.
Ticker:
RDHL
Exchange:
NASDAQ
Company Type:
Company Website:
Company HQ State:
Not Provided.
Company HQ Country:
Israel
Year Founded:
2009
Main Therapeutic Focus:
Lead Product in Development:
Talicia (RHB-105)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
7
Speaker
photo
Senior VP Business Development and Licensing
RedHill Biopharma